October 2006 Briefing - HIV & AIDS
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for October 2006. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Neuropsychiatric Disorders Boost Cost of HIV Therapy
TUESDAY, Oct. 31 (HealthDay News) -- The association between highly active antiretroviral therapy and HIV-associated neuropsychiatric disorders increases the cost of managing HIV patients both before and after treatment for mental illness, according to study findings published in the Oct. 24 issue of AIDS.
Existing HIV Guidelines Offer Best Options for New Cases
TUESDAY, Oct. 31 (HealthDay News) -- Existing guidelines for the treatment of newly HIV-infected adults do indeed recommend the most effective three-drug combination of antiretroviral therapy regimens, according to a meta-analysis published in the Oct. 24 issue of AIDS.
FDA Approves Drug for Chronic Hepatitis B in Adults
THURSDAY, Oct. 26 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tyzeka (telbivudine) for the treatment of chronic hepatitis B virus (HBV) in adults. Manufactured by Novartis Pharma Stein AG in Stein, Switzerland, and marketed by Idenix Pharmaceuticals, Inc. in Cambridge, Mass., Tyzeka is a new molecular entity.
Clinicians Believe Teens Unlikely to Practice Safe Sex
THURSDAY, Oct. 26 (HealthDay News) -- Despite their conviction that teens should be counseled on safe sex practices including monogamy, abstinence and condom use to prevent human papillomavirus (HPV) infection, fewer than one-quarter of clinicians believe adolescents will use these methods in the long run, according to a report in the Oct. 20 issue of the Morbidity and Mortality Weekly Report.
Proteolysis Elevated in HIV+ with Insulin Resistance
FRIDAY, Oct. 13 (HealthDay News) -- Fasting proteolysis is significantly higher in patients with HIV infection who have impaired glucose tolerance (IGT) than in HIV-negative patients and HIV-infected patients without IGT, according to a report published in the October issue of Diabetes. The increase in proteolysis may exacerbate hyperglycemia in HIV-infected patients.
Sputum Test Quick, Accurate for Drug-Resistant TB
WEDNESDAY, Oct. 11 (HealthDay News) -- A single microscopic-observation drug-susceptibility (MODS) assay of a sputum sample provides more sensitive and faster detection of tuberculosis and multi-drug-resistant tuberculosis than conventional methods, according to study findings published in the Oct. 12 issue of the New England Journal of Medicine.
FDA Approves New Gene-Based Diagnostic Test for HIV-1
FRIDAY, Oct. 6 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first test aimed at detecting HIV-1 RNA in the blood to help diagnose and confirm infection. The APTIMA HIV-1 RNA Qualitative Assay, which is made by Gen-Probe Inc., of San Diego, Calif., may detect virus in early infection before HIV-1 antibodies surface.
FDA Approves Fifth U.S. Flu Vaccine
THURSDAY, Oct. 5 (HealthDay News) -- The U.S. Food and Drug Administration has granted accelerated approval to another influenza vaccine for use during the 2006-2007 flu season. The vaccine, FluLaval, will be distributed by GlaxoSmithKline and is the fifth flu vaccine to be approved for use in the United States.
One in 10 U.K. Men Surveyed Pay for Sex
WEDNESDAY, Oct. 4 (HealthDay News) -- One in 10 men pay for sex, almost half of whom have a partner, according to the results of a study published in the October issue of Sexually Transmitted Infections.